CHEMODNERVATION FOR CERVICAL DYSTONIA: A CLINICAL REVIEW

Main Article Content

Muhammad Atif Ameer
Danish Bhatti

Abstract

Cervical dystonia (CD) is a focal dystonia characterized by involuntary contractions of neck muscles that result in patterned movements and abnormal postures of the head and neck that have a directional quality. CD is the most common form of dystonia presenting to the movement disorders clinic. Botulinum toxin is an effective treatment for cervical dystonia. It has become the first-line treatment for cervical dystonia with a satisfactory relief of symptoms reported in more than 80% of the cases. Multiple small and large scale studies proven that fact and provided Class-A evidence for the benefit. However, 20% of the patients discontinue treatment due to adverse effects, treatment failure and other reasons. With the proper knowledge of toxins and the anatomy of the neck, much better results can be achieved with fewer and self-limiting adverse effects as compared to other modalities. However, the expert consensus recommendations are lacking to guide clinicians for optimal use of botulinum toxin for cervical dystonias. This paper discusses the different available treatments, botulinum injection techniques and the adverse effects involved with the procedure.

Article Details

How to Cite
Ameer, M. A., and D. Bhatti. “CHEMODNERVATION FOR CERVICAL DYSTONIA: A CLINICAL REVIEW”. KHYBER MEDICAL UNIVERSITY JOURNAL, Vol. 12, no. 3, Sept. 2020, pp. 253-8, doi:10.35845/kmuj.2020.20478.
Section
Narrative Review Articles

References

1. Tsui J, Eisen A, Mak E, Carruthers J, Scott A, Calne D. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985;12(4):314-6. DOI: 10.1017/S031716710003540X.
2. Simpson D, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1699-706. DOI: 10.1212/01.wnl.0000311389.26145.95.
3. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011;308(1-2):103-9. DOI: 10.1016/j.jns.2011.05.041.
4. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16(5):316-23. DOI: 10.1016/j.parkreldis.2010.03.002.
5. Charles D, Brashear A, Hauser RA, Li H, Boo L, Brin MF, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012;35(5):208-14. DOI: 10.1097/WNF.0b013e31826538c7.
6. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991;41(7):1088-91. DOI: 10.1212/wnl.41.7.1088.
7. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6(2):119-26. DOI: 10.1002/mds.870060206.
8. Velickovic M, Benabou R, Brin MF. Cervical dystonia. Drugs 2001;61(13):1921-43. DOI: 10.2165/00003495-200161130-00004.
9. Klein C, Lohmann K, Marras C, Münchau A. Hereditary dystonia overview. GeneReviews®[Internet]:University of Washington, Seattle;2017. [Accessed on: May 25, 2020]. Available from URL: https://www.ncbi.nlm.nih.gov/books/NBK1155/.
10. Tiderington E, Goodman EM, Rosen AR, Hapner ER, Johns III MM, Evatt ML, et al. How long does it take to diagnose cervical dystonia? J Neurol Sci 2013;335(1-2):72-4. DOI: 10.1016/j.jns.2013.08.028.
11. Abbruzzese G, Berardelli A, Girlanda P, Marchese R, Martino D, Morgante F, et al. Long-term assessment of the risk of spread in primary late-onset focal dystonia. J Neurol Neurosurg Psychiatry 2008;79(4):392-6. DOI: 10.1136/jnnp.2007.124594.
12. Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998;121(4):547-60. DOI: 10.1093/brain/121.4.547.
13. Claypool DW, Duane DD, Ilstrup DM, Melton III LJ. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord 1995;10(5):608-14. DOI: 10.1002/mds.870100513.
14. Marras C, Van den Eeden S, Fross R, Benedict-Albers K, Klingman J, Leimpeter A, et al. Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology 2007;69(7):676-80. DOI: 10.1212/01.wnl.0000267425.51598.c9.
15. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010;79:591-617. DOI: 10.1146/annurev.biochem.051908.125345.
16. Peng Chen Z, Morris JG, Rodriguez RL, Shukla AW, Tapia-Núñez J, Okun MS. Emerging opportunities for serotypes of botulinum neurotoxins. Toxins 2012;4(11):1196-222. DOI: 10.3390/toxins4111196.
17. Fischer A, Sambashivan S, Brunger AT, Montal M. Beltless translocation domain of botulinum neurotoxin A embodies a minimum ion-conductive channel. J Biol Chem 2012;287(3):1657-61. DOI: 10.1074/jbc.C111.319400.
18. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Inter Med 1998;129(3):221-8. DOI: 10.7326/0003-4819-129-3-199808010-00011.
19. Schiavo G, Rossetto O, Benfenati F, Poulain B, Montecucco C. Tetanus and Botulinum Neurotoxins Are Zinc Proteases Specific for Components of the Neuroexocytosis Apparatus a. Ann N Y Acad Sci 1994;710(1):65-75. DOI: 10.1111/j.1749-6632.1994.tb26614.x.
20. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365(6442):160-3. DOI: 10.1038/365160a0.
21. Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995;28(4):423-72. DOI: 10.1017/s0033583500003292.
22. Montecucco C, Schiavo G, Rossetto O. The Mechanism of Action of Tetanus and Botulinum Neurotoxins. In: Seiler JP, Kroftová O, Eybl V (eds). Toxicology - From Cells to Man. Archives of Toxicology (Supplement), 1996;Vol 18:pp342-54. Springer, Berlin, Heidelberg. DOI: 10.1007/978-3-642-61105-6_32.
23. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997;49(1):189-94. DOI: 10.1212/wnl.49.1.189.
24. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43:16-24. DOI: 10.1046/j.1526-4610.43.7s.4.x.
25. Comella C, Jankovic J, Shannon K, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65(9):1423-9. DOI: 10.1212/01.wnl.0000183055.81056.5c.
26. Pappert E, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008;23(4):510-7. DOI: 10.1002/mds.21724.
27. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86(19):1818-26. DOI: 10.1212/WNL.0000000000002560.
28. De Pauw J, Van der Velden K, Meirte J, Van Daele U, Truijen S, Cras P, et al. The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol 2014;261(10):1857-65. DOI: 10.1007/s00415-013-7220-8.
29. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence‐based review including meta‐analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004;11(6):361-70. DOI: 10.1111/j.1468-1331.2004.00845.x.
30. Kenney C, Hunter C, Jankovic J. Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22(2):193-7. DOI: 10.1002/mds.21222.
31. Comella C, Jankovic J, Truong D, Hanschmann A, Grafe S, US XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011;308(1-2):103-9. DOI: 10.1016/j.jns.2011.05.041.
32. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64(1):6-12. DOI: 10.1136/jnnp.64.1.6.
33. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992;42(4):878-82. DOI: 10.1212/wnl.42.4.878.
34. Brin M, Lew M, Adler CH, Comella C, Factor S, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–resistant cervical dystonia. Neurology 1999;53(7):1431-8. DOI: 10.1212/wnl.53.7.1431.
35. Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 2013;5(2):249-66. DOI: 10.3390/toxins5020249.
36. Contarino MF, Van Den Dool J, Balash Y, Bhatia K, Giladi N, Koelman JH, et al. Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin. Front Neurol 2017;8:35. DOI: 10.3389/fneur.2017.00035.
37. Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins (Basel) 2010;2(12):2890-913. DOI: 10.3390/toxins2122890.
38. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12(5):392-9. DOI: 10.1002/hed.2880120504.
39. Kutschenko A, Klietz M, Paracka L, Kollewe K, Schulte-Sutum A, Janssen T, et al. Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study. J Neural Transm (Vienna) 2020;127(8):1161-5. DOI: 10.1007/s00702-020-02220-z.
40. Jinnah H, Goodmann E, Rosen AR, Evatt M, Freeman A, Factor S. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 2016;263(6):1188-94. DOI: 10.1007/s00415-016-8136-x.
41. Mustalampi S, Ylinen J, Korniloff K, Weir A, Häkkinen A. Reduced Neck Muscle Strength and Altered Muscle Mechanical Properties in Cervical Dystonia Following Botulinum Neurotoxin Injections: A Prospective Study. J Mov Disord 2016;9(1):44-9. DOI: 10.14802/jmd.15035.
42. Comella C. The treatment of cervical dystonia with botulinum toxins. J Neural Transm 2008;115(4):579-83. DOI: 10.1007/s00702-007-0831-4.
43. Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C. Anterocollis: clinical features and treatment options. Med Sci Monit 2008;14(9):CR427-30.
44. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurolo 1999;246(4):265-74. DOI: 10.1007/s004150050345.